LIDDS (Local Implant Drug Delivery System) is a Swedish pharmaceutical company developing innovative pharmaceutical products based on medical need and its proprietary drug delivery technology. LIDDS was initially founded by researchers and entrepreneurs at Uppsala University, departments of pharmacy and material sciences and University of Gothenburg, departments of urology and oncology, and within the life-science incubator P.U.L.S. AB (www.pulsinvest.se), LIDDS is located in Helsingborg, Sweden, in one of Europe’s premiere biotechnology regions.
Liproca® Depot is the first product being developed by LIDDS based on this drug delivery technology. It is a novel product targeted primarily for the treatment of prostate cancer. The purpose is to reduce the side-effects significantly as well as to potentially increase the effect relative to other current treatment alternatives. The strategic, technological, clinical and pharmaceutical competences to support the comprehensive and focused development of Liproca® Depot are contained within the unique network of LIDDS and PULS.
Liproca® Depot may also have other potential applications such as benign prostate hypertrophy (BPH). Recent clinical findings support further development.